Advertisement
Canada markets open in 50 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7365
    -0.0008 (-0.10%)
     
  • CRUDE OIL

    82.66
    +1.31 (+1.61%)
     
  • Bitcoin CAD

    95,658.42
    +499.07 (+0.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,231.90
    +19.20 (+0.87%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.2280
    +0.0320 (+0.76%)
     
  • NASDAQ futures

    18,519.25
    +15.50 (+0.08%)
     
  • VOLATILITY

    13.00
    +0.22 (+1.72%)
     
  • FTSE

    7,949.82
    +17.84 (+0.22%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6821
    +0.0016 (+0.24%)
     

Does OrthoPediatrics's (NASDAQ:KIDS) Share Price Gain of 22% Match Its Business Performance?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

OrthoPediatrics Corp. (NASDAQ:KIDS) shareholders might be concerned after seeing the share price drop 12% in the last month. But that doesn't change the fact that the returns over the last year have been pleasing. Looking at the full year, the company has easily bested an index fund by gaining 22%.

View our latest analysis for OrthoPediatrics

OrthoPediatrics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

ADVERTISEMENT

OrthoPediatrics grew its revenue by 25% last year. That's a fairly respectable growth rate. While the share price performed well, gaining 22% over twelve months, you could argue the revenue growth warranted it. If the company can maintain the revenue growth, the share price could go higher still. But before deciding this growth stock is underappreciated, you might want to check out profitability trends (and cash flow)

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

NasdaqGM:KIDS Income Statement, July 15th 2019
NasdaqGM:KIDS Income Statement, July 15th 2019

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

OrthoPediatrics shareholders should be happy with the total gain of 22% over the last twelve months. Unfortunately the share price is down 6.5% over the last quarter. Shorter term share price moves often don't signify much about the business itself. If you would like to research OrthoPediatrics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.